IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
dc.contributor.author | Reck, M | |
dc.contributor.author | Liu, SV | |
dc.contributor.author | Mansfield, AS | |
dc.contributor.author | Mok, TSK | |
dc.contributor.author | Scherpereel, A | |
dc.contributor.author | Reinmuth, N | |
dc.contributor.author | Garassino, MC | |
dc.contributor.author | Carpeno, JD | |
dc.contributor.author | Califano, Raffaele | |
dc.contributor.author | Nishio, M | |
dc.contributor.author | Orlandi, F | |
dc.contributor.author | Alexander, JAA | |
dc.contributor.author | Leal, TA | |
dc.contributor.author | Cheng, Y | |
dc.contributor.author | Lee, JS | |
dc.contributor.author | Lam, S | |
dc.contributor.author | McCleland, M | |
dc.contributor.author | Deng, Y | |
dc.contributor.author | Phan, S | |
dc.contributor.author | Horn, L | |
dc.date.accessioned | 2019-12-09T17:23:31Z | |
dc.date.available | 2019-12-09T17:23:31Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Reck M, Liu SV, Mansfield AS, Mok TSK, Scherpereel A, Reinmuth N, et al. 1736OI Mpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology. 2019;30(Supplement_5):710. | en |
dc.identifier.doi | 10.1093/annonc/mdz264 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622595 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdz264 | en |
dc.title | IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany. | en |
dc.identifier.journal | Annals of Oncology | en |
refterms.dateFOA | 2020-01-21T20:19:14Z |